First Time Loading...

CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 1.68 USD 0.6% Market Closed
Updated: Apr 24, 2024

Intrinsic Value

CTMX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. [ Read More ]

The intrinsic value of one CTMX stock under the Base Case scenario is 3.09 USD. Compared to the current market price of 1.68 USD, CytomX Therapeutics Inc is Undervalued by 46%.

Key Points:
CTMX Intrinsic Value
Base Case
3.09 USD
Undervaluation 46%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
CytomX Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling CTMX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
CytomX Therapeutics Inc

Provide an overview of the primary business activities
of CytomX Therapeutics Inc.

What unique competitive advantages
does CytomX Therapeutics Inc hold over its rivals?

What risks and challenges
does CytomX Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in CytomX Therapeutics Inc recently?

Summarize the latest earnings call
of CytomX Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CytomX Therapeutics Inc.

Provide P/S
for CytomX Therapeutics Inc.

Provide P/E
for CytomX Therapeutics Inc.

Provide P/OCF
for CytomX Therapeutics Inc.

Provide P/FCFE
for CytomX Therapeutics Inc.

Provide P/B
for CytomX Therapeutics Inc.

Provide EV/S
for CytomX Therapeutics Inc.

Provide EV/GP
for CytomX Therapeutics Inc.

Provide EV/EBITDA
for CytomX Therapeutics Inc.

Provide EV/EBIT
for CytomX Therapeutics Inc.

Provide EV/OCF
for CytomX Therapeutics Inc.

Provide EV/FCFF
for CytomX Therapeutics Inc.

Provide EV/IC
for CytomX Therapeutics Inc.

Show me price targets
for CytomX Therapeutics Inc made by professional analysts.

What are the Revenue projections
for CytomX Therapeutics Inc?

How accurate were the past Revenue estimates
for CytomX Therapeutics Inc?

What are the Net Income projections
for CytomX Therapeutics Inc?

How accurate were the past Net Income estimates
for CytomX Therapeutics Inc?

What are the EPS projections
for CytomX Therapeutics Inc?

How accurate were the past EPS estimates
for CytomX Therapeutics Inc?

What are the EBIT projections
for CytomX Therapeutics Inc?

How accurate were the past EBIT estimates
for CytomX Therapeutics Inc?

Compare the revenue forecasts
for CytomX Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CytomX Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CytomX Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of CytomX Therapeutics Inc compared to its peers.

Compare the P/E ratios
of CytomX Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing CytomX Therapeutics Inc with its peers.

Analyze the financial leverage
of CytomX Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for CytomX Therapeutics Inc.

Provide ROE
for CytomX Therapeutics Inc.

Provide ROA
for CytomX Therapeutics Inc.

Provide ROIC
for CytomX Therapeutics Inc.

Provide ROCE
for CytomX Therapeutics Inc.

Provide Gross Margin
for CytomX Therapeutics Inc.

Provide Operating Margin
for CytomX Therapeutics Inc.

Provide Net Margin
for CytomX Therapeutics Inc.

Provide FCF Margin
for CytomX Therapeutics Inc.

Show all solvency ratios
for CytomX Therapeutics Inc.

Provide D/E Ratio
for CytomX Therapeutics Inc.

Provide D/A Ratio
for CytomX Therapeutics Inc.

Provide Interest Coverage Ratio
for CytomX Therapeutics Inc.

Provide Altman Z-Score Ratio
for CytomX Therapeutics Inc.

Provide Quick Ratio
for CytomX Therapeutics Inc.

Provide Current Ratio
for CytomX Therapeutics Inc.

Provide Cash Ratio
for CytomX Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for CytomX Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for CytomX Therapeutics Inc?

What is the current Free Cash Flow
of CytomX Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for CytomX Therapeutics Inc.

Financials

Balance Sheet Decomposition
CytomX Therapeutics Inc

Current Assets 182.9m
Cash & Short-Term Investments 174.5m
Receivables 3.4m
Other Current Assets 5m
Non-Current Assets 18.9m
PP&E 16.2m
Intangibles 1.7m
Other Non-Current Assets 1m
Current Liabilities 155.9m
Accounts Payable 1.5m
Accrued Liabilities 22.2m
Other Current Liabilities 132.3m
Non-Current Liabilities 93.3m
Other Non-Current Liabilities 93.3m
Efficiency

Earnings Waterfall
CytomX Therapeutics Inc

Revenue
101.2m USD
Operating Expenses
-107.7m USD
Operating Income
-6.5m USD
Other Expenses
5.9m USD
Net Income
-569k USD

Free Cash Flow Analysis
CytomX Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

CTMX Profitability Score
Profitability Due Diligence

CytomX Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
40/100
Profitability
Score

CytomX Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

CTMX Solvency Score
Solvency Due Diligence

CytomX Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
46/100
Solvency
Score

CytomX Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 2.96 USD with a low forecast of 2.27 USD and a high forecast of 3.68 USD.

Lowest
Price Target
2.27 USD
35% Upside
Average
Price Target
2.96 USD
76% Upside
Highest
Price Target
3.68 USD
119% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

CTMX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

CTMX Price
CytomX Therapeutics Inc

1M 1M
-21%
6M 6M
+32%
1Y 1Y
+3%
3Y 3Y
-82%
5Y 5Y
-83%
10Y 10Y
-87%
Annual Price Range
1.68
52w Low
1.07
52w High
2.74
Price Metrics
Average Annual Return -33.23%
Standard Deviation of Annual Returns 22.19%
Max Drawdown -93%
Shares Statistics
Market Capitalization 113.1m USD
Shares Outstanding 67 731 800
Percentage of Shares Shorted 4.95%

CTMX Return Decomposition
Main factors of price return

What is price return decomposition?

CTMX News

Last Important Events
CytomX Therapeutics Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
CytomX Therapeutics Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

113.1m USD

Dividend Yield

0%

Description

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).

Contact

CALIFORNIA
South San Francisco
151 Oyster Point Blvd, Suite 400
+16505153185.0
http://cytomx.com/

IPO

2015-10-08

Employees

174

Officers

Chairman & CEO
Dr. Sean A. McCarthy DPHIL
Senior VP, General Counsel, Chief Compliance Officer & Secretary
Mr. Lloyd A. Rowland Jr., J.D.
Senior VP, Head of Strategy & Chief Business Officer
Mr. Jeffrey Landau B.S., M.B.A.
Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer
Mr. Christopher W. Ogden
Senior VP & Chief Scientific Officer
Dr. Marcia P. Belvin Ph.D.
Vice President of Investor Relations & Corporate Communications
Dr. Chau Cheng M.B.A., Ph.D.
Show More
Senior VP & Chief Human Resources Officer
Ms. Danielle Olander-Moghadassian
Senior Vice President of Intellectual Property
Ms. Leslie Robbins
Senior VP & Chief Medical Officer
Dr. Yu-Waye Chu M.D.
Senior Vice President of Quality & Product Manufacturing
Ms. Dawn Benson
Show Less

See Also

Discover More
What is the Intrinsic Value of one CTMX stock?

The intrinsic value of one CTMX stock under the Base Case scenario is 3.09 USD.

Is CTMX stock undervalued or overvalued?

Compared to the current market price of 1.68 USD, CytomX Therapeutics Inc is Undervalued by 46%.